Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma

Anti-PD1 therapy demonstrated impressive, prolonged responses in advanced cutaneous squamous cell carcinoma (CSCC). Therapy for ICI-refractory/ineligible disease remains unclear. We performed a retrospective analysis in locally-advanced/metastatic CSCC using cetuximab across three cohorts: immediate...

Full description

Bibliographic Details
Main Authors: Julian A. Marin-Acevedo, Bethany M. Withycombe, Youngchul Kim, Andrew S. Brohl, Zeynep Eroglu, Joseph Markowitz, Ahmad A. Tarhini, Kenneth Y. Tsai, Nikhil I. Khushalani
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
cutaneous squamous cell carcinoma
immunodeficiency
therapeutics
cetuximab
immune checkpoint inhibitor
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/15/12/3180

Internet

https://www.mdpi.com/2072-6694/15/12/3180

Similar Items